MNKD - MannKind Corp logo

MannKind Corp

MNKD
Rev 3936xtop 1%20Y
Compare MNKD Hold

MannKind Corporation develops and commercializes inhaled therapeutic products for chronic diseases. Its offerings include Afrezza inhalation powder for diabetes, the V-Go insulin delivery device, and Tyvaso DPI for pulmonary hypertension.

โš•๏ธ Healthcare NASDAQ Listed 2004 $ USD
$1,000 invested 20 years ago โ†’$37today

Score Overview

1 Year
Score
Net Growth-7x
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth12.80%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score5.9
Net Growth46.11%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth421.77%
Rev TrendEvery year
Revenue Consistencyโ€”
10 Years
Score
Net Growth-134.71%
Net Trend40%
Net Income Consistency
Rev Growth125.24%
Rev Trend90%
Revenue Consistency
20 Years
Score3.9
Net Growth81.08%
Net Trend40%
Net Income Consistency
Rev Growth3936x
Rev Trend67%
Revenue Consistency
All Time
Scoreโ€”
Net Growth42.61%
Net Trend36%
Net Income Consistency
Rev Growthโ€”
Rev Trend67%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where MannKind Corp has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 20 years of fundamentals. MNKD does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-28
$ 3.35โ€”
1 Year2025-09-26
$ 5.53-39.42%
5 Years2021-09-28
$ 4.61-27.33%
10 Years2016-09-28
$ 3.059.84%
20 Years2006-09-28
$ 91.50-96.34%
All Time2004-07-28
$ 70.40-95.24%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 393M-$ 43M$ 111M
2025$ 348M$ 5M$ 171M
2024$ 285M$ 27M$ 197M
2023$ 198M-$ 11M$ 295M
2022$ 99M-$ 87M$ 170M
2021$ 75M-$ 80M$ 204M
2020$ 65M-$ 57M$ 67M
2019$ 63M-$ 51M$ 49M
2018$ 27M-$ 86M$ 71M
2017$ 11M-$ 117M$ 43M
2016$ 174M$ 125M$ 22M
2015$ 0.00-$ 368M$ 59M
2014$ 0.00-$ 198M$ 120M
2013$ 3M-$ 191M$ 70M
2012$ 35K-$ 169M$ 61M
2011$ 50K-$ 160M$ 3M
2010$ 93K-$ 170M$ 70M
2009-$ 220M$ 32M
2008$ 20K-$ 303M$ 46M
2007$ 10K-$ 293M$ 368M
2006$ 100K-$ 230M$ 436M
2005-$ 114M$ 145M
IPO2004-$ 75M$ 90M
MNKD - MannKind Corp logo

MannKind Corp fundamental performance

Between 2020 and 2025, revenue grew from $ 65M to $ 348M and net income went from -$ 57M to $ 5M. Revenue increased in every one of those 5 years; net income in 2.

Between 2005 and 2025, net income went from -$ 114M to $ 5M. Revenue increased in 13 of those 20 years; net income in 8.

MannKind Corp currently holds a 20-year HDB Score of 3.9 out of 10. How the HDB Score is calculated.

Membership

Explore MNKD with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,816 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies